Onsemi, Oracle End Week Lower, Biotechne Jumps

Onsemi, Oracle End Week Lower, Biotechne Jumps

On this episode of Stock Movers: - Onsemi (ON) shares ended the week lower following news the US chipmaker has agreed to buy Synaptics Inc., a firm that specializes in semiconductors for smart devices. - Bio-Techne (TECH) shares ended the week higher after Merck agreed to buy Bio-Techne Corporation for about $11.3 billion to bolster its life-science business, marking the German pharma and technology group’s biggest acquisition in more than a decade. - Oracle (ORCL) stock plummeted this week as concerns mount over the company's debt-load and following the news reported by the New York Times that OpenAI could delay its IPO until next year. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Banks Slide on OpenAI IPO Warning, Onsemi, Darden Lower

On this episode of Stock Movers: - Shares of Goldman Sachs (GS) slide after the New York Times reported that bankers advising OpenAI cautioned that volatility in tech stocks could dent enthusiasm for an offering. - Onsemi (ON) shares slide following news the US chipmaker has agreed to buy Synaptics Inc., a firm that specializes in semiconductors for smart devices. - Darden Restaurants (DRI) dips slightly after the restaurant chain operator reported worse-than-expected sales performance for Olive Garden, while the LongHorn’s unit topped the Street view. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Strategy Mixed, Netflix Rises, Moderna Rises After Price target Raised

On this episode of Stock Movers: - Strategy (MSTR) shares are mixed. On Friday, Billionaire Michael Saylor on Friday defended Strategy’s approach to Bitcoin. - Netflix (NFLX) shares rise. Investors weigh the company’s push into live sports despite a thinning slate of mega-hit series. - Moderna (MRNA) shares rise. Piper Sandler raised the firm's price target on Moderna to $77 from $69 and keeps an Overweight rating on the shares. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Synaptics Rises, Lumentum Falls, Acadia Pharma Jumps on Positive CHMP Drug Opinion

On this episode of Stock Movers: Synaptics (SYNA) shares rise. Onsemi has agreed to buy Synaptics Inc. in an all-stock deal that values the company at about $6.2 billion. The transaction has a total enterprise value including debt of roughly $7 billion and is expected to close in mid-2027, subject to approvals. Lumentum (LITE) shares fall. U.S. optical communication stocks dropped. This comes as Semiconductor stocks are broadly lower. Acadia Pharma (ACAD) shares climb as much as 12%, the most intraday since May 2025, after the drugmaker said the European Medicines Agency’s CHMP issued a positive opinion for its drug to treat symptoms of Rett syndrome and recommended granting a marketing authorization. See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.

Onsemi to Buy Synaptics; Rocket Lab Extends Gain; Microsoft Eyes Worst Month Since 2000

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - US chipmaker Onsemi (ON) has agreed to buy Synaptics (SYNA), a firm that specializes in semiconductors for smart devices, in an all-stock deal that values the company at about $6.2 billion. - Rocket Lab (RKLB) shares rise as the space firm says NASA selected it to provide three Electron launches for two missions, PolSIR and TSIS-2, from early 2027. - Microsoft (MSFT) shares are down, with the software giant extending a recent selloff. The stock is down more than 20% this month, putting it on track for its biggest one-month percentage drop since December 2000 See omnystudio.com/listener [https://omnystudio.com/listener] for privacy information.